Bullous pemphigoid: from the clinic to the bench

Di Zenzo, Giovanni; Della Torre, Rocco; Zambruno, Giovanna; Borradori, Luca (2012). Bullous pemphigoid: from the clinic to the bench. Clinics in dermatology, 30(1), pp. 3-16. New York, N.Y.: Elsevier 10.1016/j.clindermatol.2011.03.005

Full text not available from this repository.

Bullous pemphigoid (BP) constitutes the most frequent autoimmune subepidermal blistering disease. It is associated with autoantibodies directed against the BP antigens 180 (BP180, BPAG2) and BP230 (BPAG1-e). The pathogenicity of anti-BP180 antibodies has been convincingly demonstrated in animal models. The clinical features of BP are extremely polymorphous. The diagnosis of BP critically relies on immunopathologic findings. The recent development of novel enzyme-linked immunosorbent assays has allowed the detection of circulating autoantibodies with relatively high sensitivity and specificity. Although potent topical steroids have emerged in the past decade as first-line treatment of BP, management of the disease may be challenging.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology
UniBE Contributor:	Borradori, Luca
ISSN:	0738-081X
Publisher:	Elsevier
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:38
Last Modified:	05 Dec 2022 14:12
Publisher DOI:	10.1016/j.clindermatol.2011.03.005
PubMed ID:	22137222
Web of Science ID:	000298212600002
URI:	https://boris.unibe.ch/id/eprint/15479 (FactScience: 222826)